Hermes Biosciences

Hermes Biosciences is a private, pre-revenue platform company commercializing the EVoE System, an automated benchtop instrument for isolating extracellular vesicles. The technology, licensed from Stanford University and based on the ExoTIC (exosome total isolation chip) nanofiltration method, is designed to overcome the yield, purity, and reproducibility challenges that have hindered EV research and therapeutic development. With a recently closed seed funding round, the company is positioned to scale its technology to accelerate biomarker discovery and the development of EV-based diagnostics and therapeutics, targeting a significant and growing market in precision medicine.

EVoE System: An automated, benchtop platform using nanofiltration-based cartridges (based on the ExoTIC technology from Stanford) for high-yield, high-purity isolation of extracellular vesicles (exosomes) from biological fluids and cell culture media.

Hermes competes with numerous companies offering EV isolation kits (e.g., from System Biosciences, Qiagen, Thermo Fisher) based on precipitation, affinity, or ultracentrifugation principles, as well as other microfluidic startups. Its key differentiators are the claimed combination of full automation, high yield, and preservation of vesicle integrity using its proprietary nanofiltration approach.